Targeting the autophagy-lysosomal pathway in Huntington disease: a pharmacological perspective

Frontiers in Aging Neuroscience

Neuroscience

Chaoyue Zhang¹  Junsheng Yang² 

[1] Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China;null;

关键词: autophagy-lysosomal pathway;    Huntington disease;    mHTT;    aggrephagy;    targeted protein degradation;   

DOI  :  10.3389/fnagi.2023.1175598

 received in 2023-02-27, accepted in 2023-05-12,  发布年份 2023

来源: Frontiers

【 摘 要 】

The autophagy-lysosomal pathway (ALP) is the major biological pathway responsible for clearing intracellular protein aggregates, therefore a promising target for treating diseases featuring the accumulation of aggregation-prone proteins, such as Huntington disease (HD). However, accumulating evidence indicated that targeting ALP to treat HD is pharmacologically challenging due to the complexity of autophagy and the autophagy defects in HD cells. Here in this mini-review, we summarized the current challenges in targeting ALP in HD and discussed a number of latest findings on aggrephagy and targeted protein degradation, which we believe will provide potential new targets and new strategies for treating HD via ALP.

【 授权许可】

Unknown   
Copyright © 2023 Yang and Zhang.